Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke

Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial

(2020) Michael D Hill et al.   LANCET

Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: a phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial

(2019) Jie Xu et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Effect of Edaravone on Neurological Symptoms in Real-World Patients With Acute Ischemic Stroke

(2019) Susumu Kobayashi et al.   STROKE

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

(2019) William J. Powers et al.   STROKE

2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

(2018) William J. Powers et al.   STROKE

Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Mohsen Naghavi et al.   LANCET

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial

(2017) Jacob Elkins et al.   LANCET NEUROLOGY

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

(2017) Koji Abe et al.   LANCET NEUROLOGY

Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013

(2016) Maigeng Zhou et al.   LANCET

Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation

(2016) Ángel Chamorro et al.   LANCET NEUROLOGY

ALIAS (Albumin in Acute Ischemic Stroke) Trials

(2016) Renee’ H. Martin et al.   STROKE

Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: A target of uric acid treatment

(2015) Yara Onetti et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke

(2015) Jeffrey L. Saver et al.   NEW ENGLAND JOURNAL OF MEDICINE

The synergetic effect of edaravone and borneol in the rat model of ischemic stroke

(2014) Hai-Yin Wu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial

(2014) Ángel Chamorro et al.   LANCET NEUROLOGY

High-dose albumin treatment for acute ischaemic stroke (ALIAS) part 2: a randomised, double-blind, phase 3, placebo-controlled trial

(2013) Myron D Ginsberg et al.   LANCET NEUROLOGY

Borneol, a Bicyclic Monoterpene Alcohol, Reduces Nociceptive Behavior and Inflammatory Response in Mice

(2013) Jackson Roberto Guedes da Silva Almeida et al.   TheScientificWorldJOURNAL

II. Cerebral Infarction/Transient Ischemic Attack (TIA)

(2011) Yukito Shinohara et al.   Journal of Stroke & Cerebrovascular Diseases

A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

(2010) Paul A Lapchak   EXPERT OPINION ON PHARMACOTHERAPY

Protection by borneol on cortical neurons against oxygen-glucose deprivation/reperfusion: involvement of anti-oxidation and anti-inflammation through nuclear transcription factor κappaB signaling pathway

(2010) R. Liu et al.   NEUROSCIENCE

NXY-059 for the Treatment of Acute Stroke

(2008) Hans-Christoph Diener et al.   STROKE